- Home
- / Zhengye Biotechnology Holding
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Zhengye Biotechnology Holding financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
¥116.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 214.1M | 260.3M | 211.7M | 186.4M | 116.4M |
| Cost of goods sold | 72.7M | 88.0M | 57.9M | 70.9M | 66.6M |
| Gross profit | 141.4M | 172.3M | 153.8M | 117.2M | 49.8M |
| Gross profit margin, % | 66.1% | 66.2% | 72.7% | 62.9% | 42.8% |
| Operating expense total | 71.5M | 86.7M | 78.5M | 76.6M | 92.9M |
| Depreciation and amortization | 17.5M | 19.8M | 34.0M | 24.2M | 25.9M |
| EBITDA | 69.9M | 85.6M | 75.2M | 40.6M | (43.2M) |
| EBITDA margin, % | 32.7% | 32.9% | 35.5% | 21.8% | -37.1% |
| EBIT | 54.0M | 66.6M | 44.2M | 17.5M | (66.9M) |
| EBIT margin, % | 25.2% | 25.6% | 20.9% | 9.4% | -57.5% |
| Interest income | 112.0K | 114.0K | 312.0K | 231.0K | 96.0K |
| Interest expense | 1.0M | 2.8M | 4.4M | 4.0M | 3.4M |
| Pre tax profit | 53.1M | 63.9M | 43.8M | 14.4M | (71.9M) |
| Income tax expense | 6.6M | 8.2M | 6.3M | 924.0K | 11.1M |
| Net Income | 46.5M | 55.7M | 37.5M | 13.5M | (83.0M) |